ARMP Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
2.5M
+218.1%
789.0K
-27.3%
1.1M
-6.4%
1.2M
-46.6%
2.2M
Cost of Revenue
0
0
0
0
0
Gross Profit
2.5M
+218.1%
789.0K
-27.3%
1.1M
-6.4%
1.2M
-46.6%
2.2M
Operating Expenses
12.8M
+33.9%
9.6M
-35.8%
14.9M
+66.8%
8.9M
-0.9%
9.0M
R&D
7.6M
+24.1%
6.1M
+0.7%
6.1M
+4.2%
5.8M
-8.9%
6.4M
SG&A
5.2M
+51.2%
3.5M
+1.1%
3.4M
+10.1%
3.1M
+18.8%
2.6M
Operating Income
-10312000
-17.4%
-8785000
+36.4%
-13823000
-77.8%
-7776000
-13.6%
-6844000
EBITDA
-9721000
-16.7%
-8328000
-4.2%
-7993000
-7.9%
-7406000
-14.3%
-6478000
Net Income
74.1M
+164.3%
-115346000
+7.2%
-124298000
-366.0%
-26675000
-63.7%
-16295000
EPS (Basic)
$2.02
+163.9%
$-3.16
+7.6%
$-3.42
-362.2%
$-0.74
-64.4%
$-0.45
EPS (Diluted)
$-0.27
+91.5%
$-3.16
+66.8%
$-9.52
-1186.5%
$-0.74
-64.4%
$-0.45
Shares (Diluted)
62.0M
+69.8%
36.5M
+179.7%
13.1M
-64.0%
36.2M
+0.1%
36.2M
Armata Pharmaceuticals (ARMP) โ€” Financials